Bone Biologics product promotes bone growth — 4 insights

Written by Eric Oliver | January 09, 2020 | Print  |

Orthobiologic developer Bone Biologics said its rhNELL-1 product promoted bone formation in advanced spine models.

What you should know:

1. Bone Biologics concluded a preclinical study of rhNELL-1. Researchers found the product was well tolerated with no inflammation.

2. Bone Biologics intends to build on the preclinical results and launch a clinical trial at a later date.

3. Researchers tested the rhNELL-1 product on sheep, finding increases in fusion and quantity of bone when compared to a control.

4. Bone Biologics received approval to test rhNELL-1 on 30 patients in Australia in a multicenter pilot clinical trial.

More articles on biologics: 
Dr. Bryan Little appointed to state medical board, task force
Former Medtronic, Bioventus executive becomes CEO at BlueWind Medical
Exactech co-founders retire, current CEO to transition to board role — 4 insights

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months